| TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC (NCT07074106) | D'Or Institute for Research and Education | 2025-10-31 |
| Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo (NCT07172347) | Jiangsu vcare pharmaceutical technology co., LTD | 2025-10-31 |
| Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) (NCT07036003) | Dr. David Wasserstein | 2025-10-31 |
| Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension (NCT07177703) | Shanghai Zhongshan Hospital | 2025-10-31 |
| Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (NCT07197307) | Universität Münster | 2025-10-31 |
| HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. (NCT07233070) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2025-10-31 |
| NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis (NCT04129515) | Brown University | 2025-10-30 |
| Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL (NCT07538180) | Sun Yat-sen University | 2025-10-30 |
| A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy (NCT06730932) | RenJi Hospital | 2025-10-30 |
| Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) (NCT07123155) | Shionogi | 2025-10-30 |
| A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (NCT07219615) | Pfizer | 2025-10-30 |
| A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis (NCT07201051) | GlaxoSmithKline | 2025-10-30 |
| A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks (NCT06851559) | Phathom Pharmaceuticals, Inc. | 2025-10-30 |
| Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. (NCT07192068) | UNICANCER | 2025-10-30 |
| A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC) (NCT07054242) | Yantai Yuhuangding Hospital | 2025-10-30 |
| Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis (NCT06794229) | Qian Qin | 2025-10-30 |
| An Exploratory Study of Golidocitinib in Adult Patients With ITP (NCT07196163) | Peking University People's Hospital | 2025-10-30 |
| QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC (NCT07330596) | Anhui Provincial Cancer Hospital | 2025-10-30 |
| The Long COVID Treatment Trial (NCT07128082) | Scripps Translational Science Institute | 2025-10-30 |
| Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults (NCT07252921) | Jiangsu HengRui Medicine Co., Ltd. | 2025-10-30 |
| A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease (NCT07231679) | Ingenia Therapeutics INC | 2025-10-30 |
| PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma (NCT07128290) | Federation Francophone de Cancerologie Digestive | 2025-10-30 |
| A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (NCT07332000) | Candel Therapeutics, Inc. | 2025-10-30 |
| Safety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients (NCT04480619) | Advanced Imaging Projects, LLC | 2025-10-30 |
| Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a) (NCT07327840) | Kylonova (Xiamen) Biopharma co., LTD. | 2025-10-29 |
| A Study of Ivonescimab in First-Line ES-SCLC (NCT07245446) | Akeso | 2025-10-29 |
| Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients (NCT07096609) | Asan Medical Center | 2025-10-29 |
| A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome (NCT07181837) | MavriX Bio, LLC | 2025-10-29 |
| Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial (NCT07155317) | Emory University | 2025-10-29 |
| BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation (NCT07246031) | BioPhoenix Co., Ltd. | 2025-10-29 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. (NCT07110662) | Hospices Civils de Lyon | 2025-10-29 |
| A Clinical Trial to Investigate the Effect of Pollen Extracts on Menopausal Symptoms in Healthy Women. (NCT06889753) | Graminex LLC | 2025-10-29 |
| Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis (NCT07192939) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2025-10-29 |
| A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors (NCT07208773) | MediLink Therapeutics (Suzhou) Co., Ltd. | 2025-10-29 |
| A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) (NCT07225959) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2025-10-29 |
| Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD (NCT06878560) | United Therapeutics | 2025-10-29 |
| PKB171 Against Placebo in Couples With Mild Male Factor Infertility (NCT07669584) | Prokrea BCN, S.L. | 2025-10-28 |
| Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD (NCT06659445) | ONL Therapeutics | 2025-10-28 |
| Study of Cannabidiol and Neuroimaging on Stress (NCT07278505) | Icahn School of Medicine at Mount Sinai | 2025-10-28 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab (NCT06701656) | PPD Development, LP | 2025-10-28 |
| Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC (NCT07120282) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-28 |
| Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA (NCT05904626) | Elgan Pharma Ltd. | 2025-10-28 |
| A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation (NCT07217067) | Novartis Pharmaceuticals | 2025-10-28 |
| ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (NCT07037420) | Alexion Pharmaceuticals, Inc. | 2025-10-28 |
| A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor (NCT07140393) | Jiangsu HengRui Medicine Co., Ltd. | 2025-10-28 |
| QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial (NCT07286253) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2025-10-28 |
| Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication (NCT05585229) | University of British Columbia | 2025-10-27 |
| Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis (NCT07263425) | The First Affiliated Hospital with Nanjing Medical University | 2025-10-27 |
| A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer (NCT06992258) | Criterium, Inc. | 2025-10-27 |
| Extended-release Sodium Oxybate in Children (NCT06809803) | Stanford University | 2025-10-27 |
| A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis (NCT07175233) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2025-10-27 |
| 129 Xenon Imaging in Patients Treated With Sotatercept (NCT06351345) | Bastiaan Driehuys | 2025-10-27 |
| Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes (NCT06948825) | George Washington University | 2025-10-27 |
| SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer (NCT07162714) | Zhejiang Cancer Hospital | 2025-10-27 |
| Extended-release Buprenorphine as a Novel Low-dose Induction Strategy (NCT06441604) | Brigham and Women's Hospital | 2025-10-27 |
| Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D) (NCT07226297) | n-Lorem Foundation | 2025-10-27 |
| A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer (NCT07223567) | M.D. Anderson Cancer Center | 2025-10-27 |
| - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (NCT06856837) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2025-10-27 |
| Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer (NCT06954480) | Queen Mary University of London | 2025-10-27 |
| Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) (NCT06835049) | Swiss Cancer Institute | 2025-10-27 |
| Assess Impact of Poly-L-lactic Acid on GLP1 Subjects (NCT07217743) | Goldman, Butterwick, Fitzpatrick and Groff | 2025-10-27 |
| A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. (NCT07641634) | Prolium Bioscience, Inc | 2025-10-27 |
| Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells (NCT07199569) | Bavarian Nordic | 2025-10-27 |
| Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer (NCT07216248) | University of Utah | 2025-10-27 |
| The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy (NCT06599697) | University of Alabama at Birmingham | 2025-10-27 |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis (NCT07499700) | Bio-Thera Solutions | 2025-10-26 |
| Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention (NCT07282184) | Tongji Hospital | 2025-10-26 |
| Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC (NCT07296705) | Fujian Medical University Union Hospital | 2025-10-25 |
| A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery (NCT07185594) | Shandong Suncadia Medicine Co., Ltd. | 2025-10-24 |
| A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease (NCT07128628) | Bausch & Lomb Incorporated | 2025-10-24 |
| ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy (NCT07218887) | Alexion Pharmaceuticals, Inc. | 2025-10-24 |
| Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (NCT07168902) | Bausch & Lomb Incorporated | 2025-10-24 |
| Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. (NCT07372365) | The First Affiliated Hospital of Soochow University | 2025-10-24 |
| A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (NCT07256782) | Qilu Pharmaceutical Co., Ltd. | 2025-10-24 |
| A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients (NCT07171606) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-10-24 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections. (NCT07420985) | Valenta Pharm JSC | 2025-10-24 |
| Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders (NCT07075510) | University of Maryland, Baltimore | 2025-10-23 |
| Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis (NCT07220408) | Telios Pharma, Inc. | 2025-10-23 |
| Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health (NCT07189234) | University of California, San Diego | 2025-10-23 |
| A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer (NCT07263386) | The First Affiliated Hospital with Nanjing Medical University | 2025-10-23 |
| A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) (NCT07076121) | Bristol-Myers Squibb | 2025-10-23 |
| Levetiracetam for Persons at Risk for Alzheimer's Disease (NCT07477431) | Sunnybrook Health Sciences Centre | 2025-10-23 |
| Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury (NCT07086755) | Paul Potnuru | 2025-10-23 |
| A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy (NCT07091305) | Shanghai Chest Hospital | 2025-10-23 |
| Treatment of Sebaceous Hyperplasia With PDL and Nd:YAG Versus Erbium:YAG: A Randomized Controlled Trial (NCT04429607) | Northwestern University | 2025-10-23 |
| Improving 24-hour Blood Pressure Stability in Spinal Cord Injury With Low Oxygen Therapy (NCT06691165) | Glen Foster | 2025-10-23 |
| A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older (NCT07311148) | Guangzhou Patronus Biotech Co., Ltd. | 2025-10-23 |
| Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) (NCT07221565) | Truway Health, Inc. | 2025-10-23 |
| Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation (NCT07267949) | Acesion Pharma | 2025-10-22 |
| Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy (NCT07220811) | RAPT Therapeutics, Inc. | 2025-10-22 |
| High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer (NCT06492759) | Emory University | 2025-10-22 |
| Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM (NCT06974604) | Brown University | 2025-10-22 |
| A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma (NCT06942442) | Sarcoma Alliance for Research through Collaboration | 2025-10-22 |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer (NCT07508852) | Peking University First Hospital | 2025-10-22 |
| A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma (NCT07229417) | M.D. Anderson Cancer Center | 2025-10-22 |
| Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma (NCT07251413) | Instituto Oncológico Dr Rosell | 2025-10-22 |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma (NCT07219173) | Eli Lilly and Company | 2025-10-22 |
| Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography (NCT07409753) | Wake Forest University Health Sciences | 2025-10-22 |
| The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer (NCT07257653) | Zhejiang University | 2025-10-21 |
| STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma (NCT06880523) | Canadian Cancer Trials Group | 2025-10-21 |